Astrazeneca FY2026 EPS Forecast Reduced by Erste Group Bank

Astrazeneca Plc (NYSE:AZN) – Research analysts at Erste Group Bank lowered their FY2026 earnings per share estimates for shares of Astrazeneca in a research report issued to clients and investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now expects that the company will post earnings per share of $10.31 for the year, down from their prior estimate of $10.52. The consensus estimate for Astrazeneca’s current full-year earnings is $10.22 per share. Erste Group Bank also issued estimates for Astrazeneca’s FY2027 earnings at $11.50 EPS.

Several other equities analysts have also recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. HSBC lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $169.20 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The stock has a fifty day moving average price of $181.50 and a 200 day moving average price of $188.20. Astrazeneca has a 1-year low of $138.84 and a 1-year high of $212.71. The company has a market cap of $262.42 billion, a PE ratio of 25.41, a P/E/G ratio of 1.34 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Brighton Jones LLC lifted its stake in shares of Astrazeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares during the period. AQR Capital Management LLC boosted its holdings in Astrazeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after buying an additional 11,690 shares in the last quarter. Amundi grew its position in Astrazeneca by 54.4% during the second quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after buying an additional 3,618 shares during the period. Jump Financial LLC grew its position in Astrazeneca by 898.4% during the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after buying an additional 30,125 shares during the period. Finally, Daiwa Securities Group Inc. increased its holdings in Astrazeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after buying an additional 559 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.